



PTO/SB/08A (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/525109
Filing Date	Not yet assigned
First Named Inventor	Amould, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100747-1P US

SHEET 1 of 6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/GS/	US1	US- 6025366	02-15-2000	Merck & Co., Inc.	
/GS/	US2	US- 6340686 B1	01-22-2002	Takeda Chemical Industries, Ltd.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/GS/	AA	WO 00/53185 A1	08-14-2000			<input type="checkbox"/>
	AB	WO 99/41251 A1	08-19-1999			<input type="checkbox"/>
	AC	WO 01/70227 A1	09-27-2001			<input type="checkbox"/>
	AD	WO 02/92565 A2	11-21-2002			<input type="checkbox"/>
	AE	WO 02/66459 A1	08-29-2002			<input type="checkbox"/>
	AF	WO 00/69433 A1	11-23-2000			<input type="checkbox"/>
	AG	WO 00/04013 A1	01-27-2000			<input type="checkbox"/>
	AH	WO 99/41252 A1	08-19-1999			<input type="checkbox"/>
	AI	WO 99/21557 A1	05-06-1999			<input type="checkbox"/>
	AJ	WO 99/21553 A1	05-06-1999			<input type="checkbox"/>
↓	AK	WO 98/55479 A1	12-10-1998			<input type="checkbox"/>

Examiner Signature	/Golam Shameem/	Date Considered	05/29/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/525109
Filing Date	Not yet assigned
First Named Inventor	Arnould, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100747-1P US

SHEET 2 of 6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/GS/	AL	WO 98/55470 A1	12-10-1998			<input type="checkbox"/>
	AM	WO 98/55123 A1	12-10-1998			<input type="checkbox"/>
	AN	WO 98/55119 A1	12-10-1998			<input type="checkbox"/>
	AO	WO 98/55116 A1	12-10-1998			<input type="checkbox"/>
	AP	WO 97/21707 A1	06-19-1997			<input type="checkbox"/>
	AQ	WO 97/21704 A1	06-19-1997			<input type="checkbox"/>
	AR	WO 97/21703 A1	06-19-1997			<input type="checkbox"/>
	AS	WO 97/21435 A1	06-19-1997			<input type="checkbox"/>
	AT	WO 00/53602 A1	08-14-2000			<input type="checkbox"/>
	AU	WO 00/53181 A1	08-14-2000			<input type="checkbox"/>
	AV	WO 00/53180 A1	08-14-2000			<input type="checkbox"/>
	AW	WO 00/53179 A1	08-14-2000			<input type="checkbox"/>
	AX	WO 00/53178 A1	08-14-2000			<input type="checkbox"/>

Examiner
Signature

/Golam Shameem/

Date
Considered

05/29/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete If Known

Application Number	10/525109
Filing Date	Not yet assigned
First Named Inventor	Arnould, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100747-1P US

SHEET 3 of 6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/GSI	AY	WO 99/51596 A1	10-14-1999			<input type="checkbox"/>
	AZ	WO 99/51595 A1	10-14-1999			<input type="checkbox"/>
	BA	WO 99/51234 A1	10-14-1999			<input type="checkbox"/>
	BB	WO 99/51233 A1	10-14-1999			<input type="checkbox"/>
	BC	WO 99/51232 A1	10-14-1999			<input type="checkbox"/>
	BD	WO 99/51231 A1	10-14-1999			<input type="checkbox"/>
	BE	JP 4356029(A) (+ Abstract)	12-09-1992			<input type="checkbox"/>
	BF	JP 4179949(A) (+ Abstract)	06-26-1992			<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Examiner Signature /Golam Shameem/

Date
Considered

05/29/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/525109
	Filing Date	Not yet assigned
	First Named Inventor	Arnould, Jean-Claude
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
SHEET 4 of 6		Attorney Docket No. 100747-1P US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/GS/	BG	ASHTON et al. 'Substituted Indole-5-carboxamides and -acetamides as Potent Nonpeptide GnRH Receptor Antagonist.' Bioorganic & Medicinal Chemistry Letters 2001, vol. 11, pp. 1723-1726.	<input type="checkbox"/>
	BH	ASHTON et al. 'Potent Nonpeptide GnHR Receptor Antagonists Derived from Substituted Indole-5-carboxamides and -acetamides Bearing a Pyridine Side-Chain Terminus.' Bioorganic & Medicinal Chemistry Letters 2001, vol. 11, pp. 1727-1731.	<input type="checkbox"/>
	BI	ASHTON et al. 'Orally Bioavailable, Indole-Based Nonpeptide GnHR Receptor Antagonists with High Potency and Functional Activity.' Bioorganic and medicinal Chemistry Letters 2001, vol. 11, pp. 2597 - 2602.	<input type="checkbox"/>
	BJ	CHU at al. 'Initial Structure-Activity Relationship of a Novel Class of Nonpeptidyl GnHR Receptor Antagonists: 2-Arylindoles.' Bioorganic and Medicinal Chemistry Letters 2001, vol. 11, pp. 509 - 513.	<input type="checkbox"/>
	BK	CHU et al. 'SAR Studies of novel 5-Substituted 2-Arylindoles as Nonpeptidyl GnHR Receptor Antagonists.' Bioorganic and Medicinal Chemistry Letters 2001, vol. 11, pp. 515 - 517.	<input type="checkbox"/>
	BL	FREIDINGER, R. M. 'Nonpeptide ligands for peptide and protein receptors.' Current Opinion in Chemical Biology 1999, vol. 3, pp. 395 - 406.	<input type="checkbox"/>
	BM	GOULET, M. T. 'Gonadotropin Releasing Hormone Antagonists.' Annual Reports in Medicinal Chemistry 1995, vol. 30, pp. 169 - 178.	<input type="checkbox"/>
	BN	LIN et al. '2-(3,5-Dimethylphenyl)tryptamine Derivatives That Bind to the GnHR Receptor.' Bioorganic & Medicinal Chemistry Letters 2001, vol. 11, pp. 1073 - 1076.	<input type="checkbox"/>
	BO	LIN et al. 'Heterocyclic Derivatives of 2-(3,5-Dimethylphenyl)tryptamine as GnHR Receptor Antagonists.' Bioorganic & Medicinal Chemistry Letters 2001, vol. 11, pp. 1077 - 1080.	<input type="checkbox"/>
↓	BP	SIMOENE, J. P. 'Synthesis of chiral β-methyl tryptamine-derived GnHR antagonists.' Tetrahedron Letters 2001, vol. 42, pp. 6459 - 6461.	<input type="checkbox"/>
Examiner Signature	/Golam Shameem/		Date Considered 05/29/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/525109
Filing Date	Not yet assigned
First Named Inventor	Amould, Jean-Claude
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket No.	100747-1P US

SHEET 5 of 6

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	²
/GS/	BQ	WALSH et al. 'A convergent synthesis of (S)- β -methyl-2-aryltryptamine based gonadotropin releasing hormone antagonists.' Tetrahedron, 2001, vol. 57, pp. 5233 – 5241.	<input type="checkbox"/>
	BR	YOUNG et al '2-Arylindoles as Gonadotropin Releasing Hormone (GnHR) Antagonists: Optimization of the Tryptamine Side Chain.' Bioorganic & Medicinal Chemistry Letters, 2002, vol. 12, pp. 827 – 832.	<input type="checkbox"/>
	BS	UJJAINWALLA, F. 'Total synthesis of 6- and 7-azaindole derived GnHR antagonists.' Tetrahedron Letters, 2001, vol. 42, pp. 6441 – 6445.	<input type="checkbox"/>
	BT	SIMEONE et al 'Modification of the Pyridine Moiety of Non-peptidyl Indole GnHR Receptor Antagonists.' Bioorganic & Medicinal Chemistry Letters, 2002, vol. 12, pp. 3329 – 3332.	<input type="checkbox"/>
	BU	GIBBS, J. B. 'Pharmaceutical Research in Molecular Oncology.' Cell, 1994, vol. 792, pp. 193 – 198.	<input type="checkbox"/>
	BV	WENSBO, D. 'Indole-3-pyruvic acid Oxime ethers and Thieno analogues by Heck Cyclisation. Application to the Synthesis of Thia Tryptophans' Tetrahedron, 1996, vol. 52(47), pp 14975-14988	<input type="checkbox"/>
	BW	BLAIR et al 'Thieno[3,2-b] and Thieno[2,3-b]pyrrole Bioisosteric Analogues of Hallucinogen and Serotonin Agonist N,N-Dimethyltryptamine' J. Med. Chem 1999, vol. 42, pp 1106-1111	<input type="checkbox"/>
	BX	COLBURN et al 'Condensed Thiophen Ring Systems. Part 20. Synthesis of 5-Arylthieno-[3,2-b]pyrroles and 5-Arylthieno[3,2-c]pyrazoles' Journal of the Chemical Society Perkins I 1977, pp.2436-2441	<input type="checkbox"/>
	BY	HUMPHRIES et al 'The Synthesis of 6-substituted Thieno[3,2-b]pyrroles. Analogs of Tryptophan, Tryptamine and Indoleacetic acid' The Journal of Organic Chemistry 1972, vol.37, pp.3626-3629	<input type="checkbox"/>
✓	BZ	KEENER et al 'The Synthesis of 6-Substituted Thieno[3,2-b]pyrroles' The Journal of Organic Chemistry 1968, vol.33(4), pp. 1355-1359	<input type="checkbox"/>
Examiner Signature	/Golam Shameem/		Date Considered 05/29/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	Complete If Known	
	Application Number	10/525109
	Filing Date	Not yet assigned
	First Named Inventor	Arnould, Jean-Claude
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
SHEET 6 of 6		Attorney Docket No. 100747-1P US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/GS/	AA	SRINIVASAN et al 'A New Synthesis of 5-Arylthieno[2,3-b]pyrroles and 5-Arylthieno[3,2-b]pyrroles' Synthesis 1973, 313-315	<input type="checkbox"/>
	AB	SYNDER et al 'Synthesis of the Thieno[3,2-b]pyrrole System' Journal of the American Chemical Society 1957, vol.79, pp.2556-2559	<input type="checkbox"/>
	AC	GALE et al 'Preparation and Reactions of 5-Carbethoxythieno[3,2-b]pyrrole and Some of Its Derivatives' The Journal of Organic Chemistry 1964, vol.29, pp.2160-2165	<input type="checkbox"/>
	AD	AOYAMA, T. 'Chemical & Pharmaceutical Bulletin 1981 vol.11, pp.3249-3255	<input type="checkbox"/>
	AE	GEETHA et al 'Indian Journal of Chemistry Section B 1979, vol.17B(2), pp.163-164	<input type="checkbox"/>
	AF	KUMAR et al 'Indian Journal of Chemistry Section B 1979, vol.18B(2), pp.541-543	<input type="checkbox"/>
	AG	KVITKO et al 'Zhurnal Organicheskoi Khimii 1976, vol.12(7), pp.1574-1585 (+ Abstract)	<input type="checkbox"/>
↓	AH	KVITKO et al 'Enamines of formyl derivatives of thio- and selenopyrrolone and synthesis of thieno- an selenopheno[2,3-b]pyrroles' 'Khim Geterotsiki Soedin 1973, vol.(4), pp.565-566 (+ Abstract)	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
Examiner Signature	/Golam Shameem/		Date Considered 05/29/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<p align="center">INFORMATION DISCLOSURE STATEMENT Form PTO-1449</p>	Application Details	
	First Named Inventor	Jean Claude Arnould
	Filing Date	Herewith
	Application Serial No.	Not yet assigned
	Examiner Name	Not yet assigned
	Group Art Unit	Not yet assigned
	Attorney Docket No.	100747-1P US

U.S. PATENT DOCUMENTS							
Examiner Initials	Desig. ID	Document Number	Publication Date	Name	Class	Sub Class	Filing Date if Appropriate
/GS/	AA	6,025,366	February 15, 2000	Antagonists of Gonadotropin Releasing Hormone			
/GS/	AB	6,340,686	January 22, 2002	Thienopyrimidine Compounds, their Production and Use			

FOREIGN PATENT DOCUMENTS									
Examiner Initials	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Sub Class	Filing Date	Abstract Only	English Language
/GS/	AC	00/53185	September 14, 2000	WIPO					Y
/GS/	AD	99/41251	August 19, 1999	WIPO					Y
/GS/	AE	01/70227	September 27, 2001	WIPO					Y
/GS/	AF	02/09256 5	November 21, 2002	WIPO					Y

OTHER DOCUMENTS		
(include Author, Title, Date and Place of Publication)		
Examiner Initials	Desig. ID	Document

Examiner Signature	/Golam Shameem/	Date Considered	05/29/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.